Predicting Cancer in Pancreatic Cystic Lesions Through Artificial Intelligence

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NICE · Apr 30, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "Predicting Cancer in Pancreatic Cystic Lesions Through Artificial Intelligence," is focused on using advanced technology to better predict whether certain fluid-filled growths in the pancreas, known as pancreatic cystic lesions, could turn into cancer. Researchers will create a special computer model that analyzes various types of patient information, including medical history, lab results, and imaging tests like MRIs and ultrasounds. The goal is to improve the current guidelines used to assess these cysts and help doctors make more informed decisions about patient care.

To be eligible for this study, participants must have been diagnosed with pancreatic cystic lesions and have undergone surgery based on existing guidelines. Importantly, they should not have any signs of pancreatic cancer at the time of surgery. Patients will not have to undergo any additional procedures for this study, and their personal information will be kept private and secure. The trial is not yet recruiting participants, but it aims to enhance our understanding of pancreatic cysts and their potential risks.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with PCL(s ) who underwent pancreatic surgery in one of the participant centers. Surgical indication must adhere to at least one of current guidelines on PCLs management (6), based on clinical, biochemical, and radiological (MR and/or EUS) features.
• • Pancreatic surgery B83performed for supposed increased risk of cyst(s) malignant degeneration following current guidelines on PCLs management (6).
• • Absence of clinical, biochemical, radiological, and anatomopathological evidence of pancreatic cancer at pancreatic surgery.
• • Non-opposition to the anonymous data processing by the included patients.
• Exclusion Criteria:
• • Patients presenting with evidence of pancreatic cancer at surgery.
• • PCL(s) diagnosis and treatment performed without one between EUS and pancreatic MR. surgery performed in the absence of the criteria proposed by current guidelines.
• • Unavailability of both preoperative EUS and pancreatic MR data.
• • Unavailability of postoperative PCL(s) anatomopathological analysis results.
• • SBO diagnosis performed without CT-scan.